People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Other Health Care, Pharma, Other Technology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Transcarent, Inc. | — | Other Health Care | Growth/Late | $481.0M | $5.0B | 2025 |
| Click Therapeutics, Inc. | — | Pharma | Series C | $136.7M | $332.0M | 2021 |
| PayZen Inc. | — | Other Technology | Series B | $43.6M | $217.9M | 2024 |
| HomeThrive, Inc. | — | Other Health Care | Series B | $35.3M | $131.8M | 2020 |
| ConsejoSano, Inc. | — | Other Health Care | Series B | $18.1M | $335.4M | 2017 |
| Eoshealth, Inc. | — | Other Health Care | Series A | $8.2M | $165.5M | 2014 |
| Jasper Health Inc. | — | Healthtech | Series A | $6.8M | $118.0M | 2021 |
| Global Pain Center Corp. | — | Other Technology | Series A | $6.2M | $6.7M | 2022 |
| 7wV-EssCo, Inc. | — | Other Health Care | Series A | $6.0M | $121.1M | 2018 |
| Modern Teacher LLC | — | Other Technology | Seed | $4.0M | $136.3M | 2018 |
LEE SHAPIRO at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside LEE SHAPIRO on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Glen Tullman | 4 | 12 |
| David Greenberg | 2 | 13 |
| Robert Garber | 2 | 8 |
| David Jacobs | 2 | 5 |
| Hemant Taneja | 1 | 21 |
| David Klein | 1 | 10 |
| Mohamad Makhzoumi | 1 | 10 |
| Devin Carty | 1 | 10 |
| Holly Maloney | 1 | 7 |
| Uri Geiger | 1 | 6 |
| Ittai Harel | 1 | 6 |
| David Shulkin | 1 | 5 |
| Shawn Smith | 1 | 4 |
| Christine Aylward | 1 | 4 |
| PHILLIP B. DONENBERG | 1 | 4 |
| Kira Wampler | 1 | 4 |
| Kevin Roberts | 1 | 3 |
| Muzammil Mansuri | 1 | 3 |
| Dennis Yang | 1 | 3 |
| Alex Zisson | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.